Open Access
CC BY-NC-ND 4.0 · Endosc Int Open 2017; 05(04): E282-E290
DOI: 10.1055/s-0043-102433
Original article
Eigentümer und Copyright ©Georg Thieme Verlag KG 2017

Efficacy and safety of PICOPREP tailored dosing compared with PICOPREP day-before dosing for colon cleansing: a multi-centric randomised study

Authors

  • Ralf Kiesslich

    1   Klinikdirektor ZIM II, Sprecher ZIM (Zentrum für Innere Medizin), Helios Dr. Horst Schmidt Kliniken Wiesbaden, Germany
  • Stefan Schubert

    2   Gastroenterologie am Bayerischen Platz, Berlin, Germany
  • Michael Mross

    3   Praxis Dr. med. Michael R Mross, Berlin, Germany
  • Tobias Klugmann

    4   Internistische Gemeinschaftspraxis, Leipzig, Germany
  • Michael Klemt-Kropp

    5   Medisch Centrum, Alkmaar, the Netherlands
  • Imke Behnken

    6   Internistisches Facharztzentrum Dr M Scholz, Langen, Germany
  • Gillaume Bonnaud

    7   Clinique des Cèdres, Blagnac, France
  • Eric Keulen

    8   Orbis Medisch Centrum, Sittard, the Netherlands
  • Marcel Groenen

    9   Rijnstate Arnhem, Wagnerlaan, the Netherlands
  • Michael Blaker

    10   Gastroenterologie Eppendorfer Baum, Hamburg, Germany
  • Thierry Ponchon

    11   Ed Herriot Hopìtal, Lyon, France
  • Wilfred Landry

    12   MVZ Dachau, Dachau, Germany
  • Meredin Stoltenberg

    13   Ferring Pharmaceuticals, Kay Fiskers Plads 11 Copenhagen S, Denmark
Weitere Informationen

Publikationsverlauf

submitted 04. April 2016

accepted after revision 19. Januar 2017

Publikationsdatum:
03. April 2017 (online)

Preview

Abstract

Background and study aims The success of any colonoscopy procedure depends upon the quality of bowel preparation. We evaluated the efficacy and safety of a new tailored dosing (TD) regimen compared with the approved PICOPREP day-before dosing regimen (DBD) in the European Union.

Patient and methods Patients (≥ 18 years) undergoing colonoscopy were randomised (2:1) to TD (Dose 1, 10 – 18 hours; Dose 2, 4 – 6 hours before colonoscopy) or DBD (Dose 1 before 8:00AM on the day before colonoscopy; Dose 2, 6 – 8 hours after Dose 1). The primary endpoint of overall colon cleansing efficacy was based on total Ottawa Scale (OS) scores (0 – 14, excellent-worst). The key secondary endpoint was a binary endpoint based on the ascending colon OS (success 0 or 1, failure [≥ 2]). Convenience and satisfaction were evaluated similar to the primary and key secondary endpoints. Safety and tolerability were also evaluated.

Results Use of the PICOPREP TD regimen resulted in a statistically significant reduction in the mean total Ottawa Scale score compared to the PICOPREP DBD regimen (–3.93, 95 % confidence intervals [CI]: – 4.99, – 2.97; P < 0.0001) in the intent-to-treat analysis set. The PICOPREP TD regimen also resulted in a statistically significant increase in the odds of achieving an ascending colon OS score ≤ 1, compared to the PICOPREP DBD regimen (estimated odds ratio 9.18, 95 % CI: 4.36, 19.32; P < 0.0001). There was no statistically significant difference in the overall rate of treatment-emergent adverse events (12 % (TD) and 5.7 % (DBD), respectively, P = 0.2988). The convenience and satisfaction were comparable in the two groups.

Conclusion The TD regimen was superior to the DBD regimen for overall and ascending colon cleansing efficacy.

ClinicalTrials.gov Identifier: NCT02239692